Bibliothek

feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
  • Necrotizing enterocolitis  (1)
  • Prostaglandin E2  (1)
  • 1
    Digitale Medien
    Digitale Medien
    Springer
    Pediatric surgery international 7 (1992), S. 421-427 
    ISSN: 1437-9813
    Schlagwort(e): Necrotizing enterocolitis ; Complications ; Operative treatment ; Mortality
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract From 1975 to 1991, 132 patients with necrotizing enterocolitis (NEC) were treated at the Department of Pediatric Surgery in Graz. Two of 49 conservatively treated patients died (4%), 1 of these was not operated upon due to complex additional malformations, and the other, a baby with 860 g birth weight (BW), could not be resuscitated sucessfully. Eighty-three patients were treated operatively, 78% with intestinal resection and exteriorization of the bowel. The mean gestational age (GA) was 36 weeks, the mean BW 2,400 g. Nearly all the patients had a medical history of one or more of the well-known predisposing risk factors; 65% had an intestinal perforation at laparotomy, 25% a transmural intestinal necrosis, and 10% pneumatosis or hemorrhagic inflammation of the intestine. Overall mortality in operated patients was 21.7% (n = 18), including 4 deaths in patients with total intestinal necrosis. There were 12 operative deaths, mainly due to progressive septicemia or total intestinal necrosis, and 6 late deaths due to infection, congenital heart disease, or cerebral disease. The mortality declined from 34% before 1985 to 7.7% after 1985 and 6.3% in the last 5 years of this study. Thirty operative complications consisted chiefly of late stenoses, ileus, or late anastomotic complications. Among these patients, only 1 with septicemia after ileostomy closure died. In contrast, all major nonoperative complications caused death, primarily due to infectious problems with septicemia. Mature granulocytes at admission were significantly higher among operated survivors (42.9% vs 23.0%) and represented a valuable predictor of patient survival. In conclusion, despite some differences in this population group with respect to the literature (higher GA and BW), the results show a definite increase in survival, reaching more than 90% of operated patients with NEC.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    ISSN: 1437-9813
    Schlagwort(e): Congenital biliary atresia ; Prostaglandin E2 ; Ursodeoxycholic acid
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract Nineteen patients with type III congenital biliary atresia (CBA) were treated by portoenterostomy. In the histological sections, bile ductule diameters below 100 μm and age-dependent liver fibrosis of grade II–IV were found. In group A, 8 patients received no postoperative choleretic therapy; in group B, 6 patients were treated with prostaglandin E2 (PG E2); and in group C, in 5 patients ursodeoxycholic acid (UDCA) was added to the PG E2 therapy. In the first 3 postoperative months a significant beneficial effect of PG E2 was observed as reduced serum bilirubin and aspartate aminotransferase (AST) levels relative to the untreated group. In group C (UDCA and PG E2) significantly lower serum levels of all liver parameters relative to the untreated group and gradually decreased levels of bilirubin, alanine aminotransferase (ALT), g-glutamyl transferase (GGT), and higher cholinesterase (CHE) activity were observed than in the PG E2 group. During episodes of cholangitis steroids were also added, but alterations in serum bilirubin levels, CHE activity, and bile flow did not improve after any adjunctive therapy. Liver enzyme activity was immediately elevated in groups A and B, but significantly lower in group C. The efficacy of both drugs, PG E2 and UDCA, lasted only for the first 3 post-operative months and failed to improve or delay the progression of hepatic damage. After portoenterostomy, 13 patients (68%), died within 6–32 months, 12 from progressive liver failure and 1 after liver transplantation. Six patients (32%) are alive, 3 after liver transplantation; 2 are jaundice-free and 1 jaundiced patient is on a waiting list for transplantation. In these prognostically poor patients with type III CBA, early liver transplantation is the only feasible option as adjuvant Pg E2, UDCA, and corticosteroid therapy demonstrated no long-term improvement after portoenterostomy.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...